|
rs10748835
|
AS3MT;BORCS7-ASMT;LOC107984265
|
Acute Promyelocytic Leukemia
|
|
0.010 |
GeneticVariation |
BEFREE |
Our data promotes the realization that AS3MT 35587 (rs11191453), 35991 (rs10748835), especially their joint genotypes 35991 (rs10748835) AA / 35587 (rs11191453) TC+CC, is a novel predictive biomarker for the therapeutic efficacy of As<sub>2</sub>O<sub>3</sub> in the treatment of APL.
|
31330140 |
2019 |
|
rs11191439
|
AS3MT;BORCS7-ASMT
|
Acute Promyelocytic Leukemia
|
|
0.010 |
GeneticVariation |
BEFREE |
In this article, the associations among urinary arsenic profiles, hematological and biochemical values, and 3 AS3MT genotypes (rs3740392, rs3740390, and rs11191439) were evaluated in 50 APL patients treated with arsenic trioxide (As2O3).
|
30376134 |
2018 |
|
rs11191453
|
AS3MT;BORCS7-ASMT;LOC107984265
|
Acute Promyelocytic Leukemia
|
|
0.010 |
GeneticVariation |
BEFREE |
Our data promotes the realization that AS3MT 35587 (rs11191453), 35991 (rs10748835), especially their joint genotypes 35991 (rs10748835) AA / 35587 (rs11191453) TC+CC, is a novel predictive biomarker for the therapeutic efficacy of As<sub>2</sub>O<sub>3</sub> in the treatment of APL.
|
31330140 |
2019 |
|
rs3740390
|
AS3MT;BORCS7-ASMT
|
Acute Promyelocytic Leukemia
|
|
0.010 |
GeneticVariation |
BEFREE |
These results indicate that inherent genetic information of the AS3MT rs3740390 genotypes is a novel predicted or evaluated target for As2O3-induced side effects and therapeutic efficacy for the treatment of APL.
|
30376134 |
2018 |
|
rs7909591
|
AS3MT;BORCS7-ASMT;LOC107984265
|
Alcohol consumption
|
T |
0.700 |
GeneticVariation |
GWASCAT |
Novel genetic associations for blood pressure identified via gene-alcohol interaction in up to 570K individuals across multiple ancestries.
|
29912962 |
2018 |
|
rs12765002
|
AS3MT;BORCS7-ASMT
|
Anxiety
|
T |
0.700 |
GeneticVariation |
GWASCAT |
Meta-analysis of genome-wide association studies for neuroticism in 449,484 individuals identifies novel genetic loci and pathways.
|
29942085 |
2018 |
|
rs3740393
|
AS3MT;BORCS7-ASMT
|
Anxiety
|
C |
0.700 |
GeneticVariation |
GWASCAT |
Meta-analysis of genome-wide association studies for neuroticism in 449,484 individuals identifies novel genetic loci and pathways.
|
29942085 |
2018 |
|
rs11191454
|
AS3MT;BORCS7-ASMT;LOC107984265
|
Attention deficit hyperactivity disorder
|
|
0.810 |
GeneticVariation |
BEFREE |
Our results provide preliminary evidence for the overtransmission of the A allele at the AS3MT rs11191454 polymorphism in ADHD.
|
25461954 |
2015 |
|
rs11191454
|
AS3MT;BORCS7-ASMT;LOC107984265
|
Attention deficit hyperactivity disorder
|
|
0.810 |
GeneticVariation |
GWASDB |
Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis.
|
23453885 |
2013 |
|
rs11191454
|
AS3MT;BORCS7-ASMT;LOC107984265
|
Attention deficit hyperactivity disorder
|
|
0.810 |
GeneticVariation |
GWASCAT |
Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis.
|
23453885 |
2013 |
|
rs11191454
|
AS3MT;BORCS7-ASMT;LOC107984265
|
Autistic Disorder
|
|
0.010 |
GeneticVariation |
BEFREE |
Therefore, this family-based association study was performed in 640 Chinese Han autism trios to investigate the association between autism and 7 SNPs with genome-wide significance in previous GWAS (rs4307059 near MSNP1AS, rs4141463 in MACROD2, rs2535629 in ITIH3, rs11191454 in AS3MT, rs1625579 in MIR137HG, rs11191580 in NT5C2, and rs1409313 in CUEDC2).
|
30610940 |
2019 |
|
rs11191454
|
AS3MT;BORCS7-ASMT;LOC107984265
|
Bipolar Disorder
|
|
0.700 |
GeneticVariation |
GWASCAT |
Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis.
|
23453885 |
2013 |
|
rs1046778
|
AS3MT;BORCS7-ASMT;LOC107984265
|
Bladder Neoplasm
|
|
0.020 |
GeneticVariation |
BEFREE |
The polymorphisms of AS3MT rs11191438, AS3MT rs10748835, and AS3MT rs1046778 were related to the risk of BC and UTUC, while the polymorphisms of AS3MT rs3740393, AS3MT rs11191453, and AS3MT rs11191454 were associated with arsenic methylation capacity.
|
29859237 |
2018 |
|
rs1046778
|
AS3MT;BORCS7-ASMT;LOC107984265
|
Bladder Neoplasm
|
|
0.020 |
GeneticVariation |
BEFREE |
High MMA%, low DMA% and AS3MT rs1046778 C/C + C/T genotype predicted a significantly higher risk of BC according to stepwise multiple logistic regression analyses.
|
29669044 |
2018 |
|
rs10748835
|
AS3MT;BORCS7-ASMT;LOC107984265
|
Bladder Neoplasm
|
|
0.020 |
GeneticVariation |
BEFREE |
The polymorphisms of AS3MT rs11191438, AS3MT rs10748835, and AS3MT rs1046778 were related to the risk of BC and UTUC, while the polymorphisms of AS3MT rs3740393, AS3MT rs11191453, and AS3MT rs11191454 were associated with arsenic methylation capacity.
|
29859237 |
2018 |
|
rs10748835
|
AS3MT;BORCS7-ASMT;LOC107984265
|
Bladder Neoplasm
|
|
0.020 |
GeneticVariation |
BEFREE |
The combination of AS3MT haplotype 2 (AS3MT rs11191453, rs11191454, rs10748835, and rs1046778)'s high-risk haplotype (C-G-A-C, T-A-A-C, and T-G-G-T) was significantly associated with increased risk of BC.
|
29669044 |
2018 |
|
rs11191438
|
AS3MT;BORCS7-ASMT
|
Bladder Neoplasm
|
|
0.010 |
GeneticVariation |
BEFREE |
AS3MT rs11191438 (C > G) G/G genotype, AS3MT rs10748835 (A > G) G/G genotype, and AS3MT rs1046778 (C > T) T/T genotype were found to be related to BC risk, where the odds ratio (OR) (95% CI) was 0.50 (0.31-0.82), 0.49 (0.30-0.79), and 0.54 (0.36-0.80), respectively.
|
29669044 |
2018 |
|
rs11191439
|
AS3MT;BORCS7-ASMT
|
Bladder Neoplasm
|
|
0.010 |
GeneticVariation |
BEFREE |
Individuals with one or more copies of the C allele in rs11191439 (the Met287Thr polymorphism) had an elevated risk of bladder cancer (OR = 1.17; 95% CI = 1.04-1.32 per 1 μg/L increase in average exposure).
|
22747749 |
2012 |
|
rs11191439
|
AS3MT;BORCS7-ASMT
|
Bladder Neoplasm
|
|
0.010 |
GeneticVariation |
BEFREE |
Individuals with one or more copies of the C allele in rs11191439 (the Met287Thr polymorphism) had an elevated risk of bladder cancer (OR = 1.17; 95% CI = 1.04-1.32 per 1 μg/L increase in average exposure).
|
22747749 |
2012 |
|
rs11191454
|
AS3MT;BORCS7-ASMT;LOC107984265
|
Bladder Neoplasm
|
|
0.010 |
GeneticVariation |
BEFREE |
The polymorphisms of AS3MT rs11191438, AS3MT rs10748835, and AS3MT rs1046778 were related to the risk of BC and UTUC, while the polymorphisms of AS3MT rs3740393, AS3MT rs11191453, and AS3MT rs11191454 were associated with arsenic methylation capacity.
|
29859237 |
2018 |
|
rs3740393
|
AS3MT;BORCS7-ASMT
|
Bladder Neoplasm
|
|
0.010 |
GeneticVariation |
BEFREE |
The polymorphisms of AS3MT rs11191438, AS3MT rs10748835, and AS3MT rs1046778 were related to the risk of BC and UTUC, while the polymorphisms of AS3MT rs3740393, AS3MT rs11191453, and AS3MT rs11191454 were associated with arsenic methylation capacity.
|
29859237 |
2018 |
|
rs12416687
|
AS3MT;BORCS7-ASMT
|
Blood Pressure
|
T |
0.700 |
GeneticVariation |
GWASDB |
Gene-age interactions in blood pressure regulation: a large-scale investigation with the CHARGE, Global BPgen, and ICBP Consortia.
|
24954895 |
2014 |
|
rs72841270
|
AS3MT;BORCS7-ASMT
|
Body Height
|
|
0.700 |
GeneticVariation |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
rs12765002
|
AS3MT;BORCS7-ASMT
|
Body mass index
|
|
0.700 |
GeneticVariation |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
rs77335224
|
AS3MT;BORCS7-ASMT
|
Body mass index
|
T |
0.700 |
GeneticVariation |
GWASCAT |
Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry.
|
30239722 |
2019 |